Inmune Bio Stock Buy Hold or Sell Recommendation
| INMB Stock | USD 7.95 0.09 1.12% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding INmune Bio is 'Hold'. Macroaxis provides INmune Bio buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding INMB positions.
Check out INmune Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide. In addition, we conduct extensive research on individual companies such as INmune and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
INmune |
Execute INmune Bio Buy or Sell Advice
The INmune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on INmune Bio. Macroaxis does not own or have any residual interests in INmune Bio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute INmune Bio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
INmune Bio Trading Alerts and Improvement Suggestions
| INmune Bio is way too risky over 90 days horizon | |
| INmune Bio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 42 K. | |
| INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 24.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Why INmune Bio, Inc. is Skyrocketing So Far in 2025 - MSN |
INmune Bio Returns Distribution Density
The distribution of INmune Bio's historical returns is an attempt to chart the uncertainty of INmune Bio's future price movements. The chart of the probability distribution of INmune Bio daily returns describes the distribution of returns around its average expected value. We use INmune Bio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of INmune Bio returns is essential to provide solid investment advice for INmune Bio.
| Mean Return | 0.91 | Value At Risk | -8.23 | Potential Upside | 12.57 | Standard Deviation | 6.09 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of INmune Bio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
INmune Stock Institutional Investors
| Shares | Deutsche Bank Ag | 2024-12-31 | 109.8 K | Northern Trust Corp | 2024-12-31 | 106 K | Mccormack Advisors International | 2024-12-31 | 100.8 K | Westside Investment Management, Inc. | 2024-12-31 | 90 K | Appleseed Capital | 2024-12-31 | 83.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 77.5 K | Two Sigma Investments Llc | 2024-12-31 | 66.4 K | Goldman Sachs Group Inc | 2024-12-31 | 63.6 K | Xtx Topco Ltd | 2024-12-31 | 61.3 K | Blackrock Inc | 2024-12-31 | 989.6 K | Praetorian Pr Llc | 2024-12-31 | 812.2 K |
INmune Bio Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 15.0M | 52.8M | (22.7M) | (16.3M) | (14.7M) | (13.9M) | |
| Net Income | (12.1M) | (30.3M) | (27.3M) | (30.0M) | (27.0M) | (25.7M) | |
| End Period Cash Flow | 22.0M | 74.8M | 52.2M | 35.8M | 41.2M | 23.6M | |
| Change To Netincome | 4.1M | 3.1M | 4.8M | 7.1M | 8.2M | 8.6M | |
| Free Cash Flow | (8.9M) | (43.5M) | (22.7M) | (12.0M) | (10.8M) | (11.3M) | |
| Other Non Cash Items | 3.2M | 126K | 328K | 224K | 257.6K | 244.7K |
INmune Bio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to INmune Bio or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that INmune Bio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a INmune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.99 | |
β | Beta against Dow Jones | 0.77 | |
σ | Overall volatility | 6.08 | |
Ir | Information ratio | 0.17 |
INmune Bio Volatility Alert
INmune Bio is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure INmune Bio's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact INmune Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.INmune Bio Fundamentals Vs Peers
Comparing INmune Bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze INmune Bio's direct or indirect competition across all of the common fundamentals between INmune Bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as INmune Bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of INmune Bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare INmune Bio to competition |
| Fundamentals | INmune Bio | Peer Average |
| Return On Equity | -0.99 | -0.31 |
| Return On Asset | -0.45 | -0.14 |
| Operating Margin | (989.21) % | (5.51) % |
| Current Valuation | 149.76 M | 16.62 B |
| Shares Outstanding | 22.69 M | 571.82 M |
| Shares Owned By Insiders | 23.95 % | 10.09 % |
| Shares Owned By Institutions | 23.87 % | 39.21 % |
| Number Of Shares Shorted | 5.39 M | 4.71 M |
| Price To Earning | (7.51) X | 28.72 X |
| Price To Book | 4.66 X | 9.51 X |
| Price To Sales | 4,295 X | 11.42 X |
| Revenue | 155 K | 9.43 B |
| Gross Profit | 42 K | 27.38 B |
| EBITDA | (29.74 M) | 3.9 B |
| Net Income | (30.01 M) | 570.98 M |
| Cash And Equivalents | 61.21 M | 2.7 B |
| Cash Per Share | 3.41 X | 5.01 X |
| Total Debt | 10.44 M | 5.32 B |
| Debt To Equity | 0.22 % | 48.70 % |
| Current Ratio | 30.87 X | 2.16 X |
| Book Value Per Share | 1.74 X | 1.93 K |
| Cash Flow From Operations | (11.98 M) | 971.22 M |
| Short Ratio | 12.87 X | 4.00 X |
| Earnings Per Share | (2.18) X | 3.12 X |
| Target Price | 23.4 | |
| Number Of Employees | 11 | 18.84 K |
| Beta | 1.94 | -0.15 |
| Market Capitalization | 180.4 M | 19.03 B |
| Total Asset | 57 M | 29.47 B |
| Retained Earnings | (121.02 M) | 9.33 B |
| Working Capital | 21.48 M | 1.48 B |
| Current Asset | 8.38 M | 9.34 B |
| Current Liabilities | 721.01 K | 7.9 B |
Note: Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3 [view details]
INmune Bio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as INmune . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About INmune Bio Buy or Sell Advice
When is the right time to buy or sell INmune Bio? Buying financial instruments such as INmune Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having INmune Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Power Assets Thematic Idea Now
Power Assets
Large capitalization equities showing high long-term performance indicators and above average return expectations based on Macroaxis rating system. The Power Assets theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Power Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out INmune Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.